<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">BMC Infect. Dis</journal-id><journal-title-group><journal-title>BMC Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4220866</article-id><article-id pub-id-type="publisher-id">1471-2334-14-S2-O2</article-id><article-id pub-id-type="doi">10.1186/1471-2334-14-S2-O2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>First-line therapy with LPV/r vs NVP and 2 NRTIs in a developing country: W144 of a randomized trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Clumeck</surname><given-names>Nathan</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Mwamba</surname><given-names>Claude</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Kabeya</surname><given-names>Kabamba</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Calvez</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Matanda</surname><given-names>Serge</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Vaira</surname><given-names>Dolor&#x000e8;s</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Peytavin</surname><given-names>Gilles</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Necsoi</surname><given-names>Coca</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Delforge</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Kadiebwe</surname><given-names>David</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Milolo</surname><given-names>Chantal</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Ilunga</surname><given-names>Joe</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Kapend</surname><given-names>Li&#x000e9;vin</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Saint Pierre University Hospital, Brussels, Belgium</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>23</day><month>5</month><year>2014</year></pub-date><volume>14</volume><issue>Suppl 2</issue><supplement><named-content content-type="supplement-title">Abstracts from the International Symposium HIV and Emerging Infectious Diseases 2014</named-content></supplement><fpage>O2</fpage><lpage>O2</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Clumeck et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Clumeck et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2334/14/S2/O2"/><conference><conf-date>21-23 May 2014</conf-date><conf-name>International Symposium HIV and Emerging Infectious Diseases 2014</conf-name><conf-loc>Marseille, France</conf-loc></conference></article-meta></front><body><sec><title>Aim</title><p>In resource-limited countries, NNRTI-based regimen may result in emergence of more HIV drug resistance because of a low genetic barrier. We compare the efficacy and tolerance of LPV/r and NVP-based regimens and 2 WHO nucleoside backbones in naive HIV infected patients (p.).</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>Naive p. from 5 clinics in Lubumbashi (Congo-DRC) were randomized to receive LPV/r versus NVP combined with TDF/FTC or ZDV/3TC. VL and CD4 were performed at baseline (BL) and every 24 weeks (W). The primary endpoint was the % of p. with therapeutic failure defined as clinical and virologic failures (VL&#x0003e;1000 c/ml)(missing data=failure), assessed at W48 and 96. We present here the results of 144 W of follow-up.</p></sec><sec sec-type="results"><title>Results</title><p>425 Black African p. (72% female; median (md) age 38 years, md CD4 165/&#x000b5;L; md VL 5.2 log c/ml) were randomized (216 in LPV/r, 209 in NVP). BL characteristics were comparable. In the ITT analysis, previous results showed no difference between LPV/r and NVP treatment arms at W96 except a higher proportion of virologic failure (VF) in p. on NVP-based regimens. W144 ITT analysis showed a significant difference on endpoints between LPV/r (94/216) and NVP (111/209)(p=0.0479) and persistence of a significant difference in VF rate (20/216 vs 37/209 for LPV/r and NVP, respectively)(p= 0.015). BL genotypes showed NNRTI mutations (mt) in 3/31 NVP-failing p. and no PI mt in LPV/r-failing patients. At time of failure, NNRTI mt were seen in 23/26 NVP-failing p. and 0/13 primary PI mt in LPV/r failing patients. NRTI mt were seen in 19/26 p. in NVP arm (including K65R in 7p. and M184V in 18p.) vs 3/13p. in LPV/r arm (M184V in 3p.).</p><p>Md CD4 change from BL was significant higher in LPV/r arm (251 cells/&#x000b5;L [interquartile range (IQR) 153;384]) compared with NVP arm (174 cells/&#x000b5;L [IQR 102-330])(p= 0.0093). Percentage of p. with adherence &#x0003e;95% was similar (73.6 vs 74.4 for LPV/r vs NVP).</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>In a resource-limited setting after 144 weeks of follow-up NNRTI-NRTI first-line regimen is associated with more virologic failure, more drug resistance mutations and a lower immunologic response than a PI-based regimen.</p></sec></body></article>